BioSpace News Archive

Arch Biopartners Inc. announced today that its lead drug candidate, LSALT Peptide (LSALT and “Metablok”) will enter the Canadian Treatments for COVID-19.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is included in the company’s ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product.

Mind Medicine today announced that MindMed’s Chief Executive Officer, Robert Barrow, will participate in a panel and Company’s management will participate in one-on-one investor meetings at the virtual H.C. Wainwright 2nd Annual Psychedelics Conference to be held on Monday, December 6, 2021.

Zetagen Therapeutics today announced it has received Breakthrough Device designation from the Centers for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA) for its ZetaMet™ technology.

Ironwood Pharmaceuticals, Inc. today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer.

VBI Vaccines Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] for the prevention of infection caused by all known subtypes of hepatitis B virus (HBV) in adults age 18 years and older.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that, in a Phase 2 proof-of-concept (POC) study in patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS).

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations, including one late-breaking abstract, will be debuted at the upcoming 2021 American Epilepsy Society (AES) annual meeting, which will be held December 3 to 7, 2021 in Chicago, IL.

SQZ Biotechnologies Company today announced that its China Initiative has been accepted by the Roche Accelerator.

Arch Therapeutics, Inc. announced today that it has added a key opinion leader (KOL) interview to its Experts in Wound Care Program, a series of interviews with key opinion leaders dedicated to advancing wound care.